RxDoctor Payments Data

Ashlynne Clark, MD

Dermatology · Cedar Rapids, IANPI 1932410867

Payments from drug & device makers

What this record shows

This record is dominated by education: $92 of the $120 with a category attached, or 77.1%. Johnson & Johnson accounts for 64.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $92 and has fallen 83.3% since, to $15 in 2023. That places this record below the midpoint for dermatology clinicians in IA, where the typical reported total is $716.

$120in general payments, 2019–2025

Across 4 payments — averaging $29.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$77
  • AbbVie$27
  • Pfizer$15
$208in research payments, 2019–2025

Across 3 payments — averaging $69.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Daiichi Sankyo Inc.$208
$109,356in ownership & investment interests, 2019–2025

Across 7 payments — averaging $15,622 each. An ownership or investment interest held by the physician or an immediate family member.

  • Digital Diagnostics Inc.$109K

What the payments were for

  • Food & beverage$2723%
  • Education$9277%

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson1$77
AbbVie(2 entities)2$27
Pfizer1$15

How this compares

$120 in reported general payments places this provider in the 15th percentile of 92 dermatology providers in Iowa.

See all dermatology providers in Iowa

Medicare billing

Part B allowed, 2024
$654,815
Medicare patients
481
Services billed
1,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluorouracil20$1,881
Doxycycline Monohydrate45$615
Cephalexin114$367
Mupirocin34$190
ValacyclovirValacyclovir Hcl13$135
Amoxicillin12$21

Paid to pharmacies, not to this prescriber.

Other dermatology in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →